MI-CP151 was a section 1b randomised, double-blind, placebo managed, dose-escalation, multicentre study to evaluate a number of intravenous doses of sifalimumab, in Grownup clients with dermatomyositis or polymyositis (NCT00533091). Primary trial objectives had been to evaluate the security and tolerability of sifalimumab in dermatomyositis or polymyositis sufferers, when one of https://geoffreyx111lwh4.oneworldwiki.com/user